Cytokinetics
Cytokinetics, Incorporated, a leading biopharmaceutical company based in the United States, focuses on the discovery and development of innovative muscle biology therapies. Founded in 1998, the company has made significant strides in the treatment of debilitating diseases, particularly in the fields of heart failure and neuromuscular disorders. With its headquarters in South San Francisco, California, Cytokinetics operates primarily in the biotechnology sector, emphasising the development of small molecule therapeutics that enhance muscle function. The company’s core products, including its investigational therapies, are distinguished by their unique mechanisms of action that target muscle contractility. Cytokinetics has garnered recognition for its commitment to advancing science and improving patient outcomes, positioning itself as a notable player in the biopharmaceutical landscape.
DitchCarbon Score
How does Cytokinetics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cytokinetics's score of 8 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cytokinetics's reported carbon emissions
In 2023, Cytokinetics reported total emissions of approximately 1,230,000 kg CO2e, comprising 391,000 kg CO2e from Scope 1 and 839,000 kg CO2e from Scope 2 emissions. This represents a reduction from 2022, where total emissions were about 1,472,000 kg CO2e, with Scope 1 emissions at 642,000 kg CO2e and Scope 2 emissions at 830,000 kg CO2e. The company's emissions intensity for 2023 was approximately 2,970 kg CO2e per employee, down from 3,560 kg CO2e per employee in 2022. Cytokinetics has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, the company is actively monitoring and reporting its emissions, indicating a commitment to transparency in its environmental impact. As a biopharmaceutical company headquartered in the US, Cytokinetics is positioned within an industry increasingly focused on sustainability and reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 642,000 | 000,000 |
| Scope 2 | 830,000 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cytokinetics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
